Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas

Zambo, Iva Staniczková; Hermanová, Markéta; Zapletalová, Danica; Škoda, J.; Múdrý, Peter; Kýr, Michal; Zitterbart, Karel; Štěrba, Jaroslav; Veselská, Renata

doi:10.3233/cbm-160623

Cited by 17 publications

(18 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al also reported an association between ABCG2 overexpression and poor prognosis for hepatocellular carcinoma in elderly patients [42]. However, a different survey found no significant relationship between ABCG2 expression and the clinical outcomes of pediatric sarcomas [43]. ABCG2 may not be enriched in sarcomas, which would explain this result.…”

Section: Discussionmentioning

confidence: 99%

Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes

Yue

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Right-sided colon cancer (RCC) has a poorer prognosis and a higher relapse rate than left-sided colon cancer (LCC). Like cancer stem cells (CSCs), RCC cells cannot be fully eradicated and are often involved in relapse or metastasis. Because CSCs may be linked with poor outcomes, CSC markers may have prognostic value in RCC. ATP-binding cassette sub-family G member 2 (ABCG2) and OCT-4 (also known as POU5F1) are among the most useful markers for CSC identification. We therefore examined the malignant behavior of ABCG2 and OCT-4 in vitro and in vivo, and their expression was assessed in pathology tissues obtained from clinicopathologically recurrent and non-recurrent cases. Our survey suggested associations between ABCG2 and OCT-4 expression and RCC clinicopathological variables. No correlations were detected between ABCG2 or OCT-4 expression and age, gender, tumor size, or tumor shape, but ABCG2 expression correlated with TNM stage, tumor differentiation, and lymphovascular invasion. Additionally, expression of both ABCG2 and OCT-4 correlated with RCC recurrence and poor outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes

Yue

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…It was observed to be a marker for neural stem and progenitor cells; thus, it was named nestin: neural stem cell protein. Furthermore, it has been proposed that nestin expression correlates with a poor prognosis in malignancies, such as glioblastoma, lung and renal carcinoma, sarcoma and skin melanoma (Piras et al 2010;Cros et al 2016;Guadagno et al 2016;Li et al 2016;Zambo et al 2016). Nestin was recently classified as a CSC marker found in various tumours of neuroectodermal or mesenchymal origin arising in the brain, oropharynx, pancreas, kidney and muscle (Krupkova et al 2010).…”

Section: Introductionmentioning

confidence: 99%

“…Nestin was recently classified as a CSC marker found in various tumours of neuroectodermal or mesenchymal origin arising in the brain, oropharynx, pancreas, kidney and muscle (Krupkova et al 2010). Furthermore, it has been proposed that nestin expression correlates with a poor prognosis in malignancies, such as glioblastoma, lung and renal carcinoma, sarcoma and skin melanoma (Piras et al 2010;Cros et al 2016;Guadagno et al 2016;Li et al 2016;Zambo et al 2016). In the latter, nestin expression was associated with more advanced tumour stages and predicted poor survival (Brychtova et al 2007;Piras et al 2010).…”

Section: Introductionmentioning

confidence: 99%

Nestin expression in primary and metastatic uveal melanoma – possible biomarker for high‐risk uveal melanoma

Djirackor

Shakir

Kalirai

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Many studies have investigated whether CD133 expression is useful for clinical outcomes, and these studies have shown that CD133 is positively related to poor prognosis in HCC patients [14], that high CD133 levels are associated with shorter survival rates in rhabdomyosarcoma patients [15], and that CD133 expression might be an unfavorable prognosis for ovarian cancer patients [16]. Two meta-analyses have shown that higher CD133 levels are significantly associated with lymph node metastasis, clinical stage, and histopathological grade in colorectal cancer and esophageal carcinoma patients [17, 18].…”

Section: Introductionmentioning

confidence: 99%

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

et al. 2017

View full text Add to dashboard Cite

BackgroundCD133 (prominin-1) is widely believed to be a cancer stem cell marker in various solid tumor types, and CD133 has been correlated with tumor-initiating capacity. Recently, the nuclear location of CD133 expression in tumors has been discussed, but hepatocellular carcinoma (HCC) has not been included in these discussions. The goal of this study was to investigate the location of CD133 expression in HCC and this location’s potential value as a prognostic indicator of survival in patients with HCC.MethodsWe enrolled 119 cancerous tissues and pair-matched adjacent normal liver tissue from HCC patients. These tissues were obtained immediately after operation, and tissue microarrays were subsequently constructed. The expression of CD133 was measured by immunohistochemistry (IHC), and the correlations between this expression and clinical characteristics and prognosis was estimated using statistical analysis.ResultsThe results showed that the CD133 protein expression levels of HCC in both the cytoplasm and nucleus were significantly higher than adjacent normal liver tissue. Kaplan–Meier survival and Cox regression analyses revealed that high CD133 expression in the cytoplasm was an independent predictor of poor prognosis for the overall survival (OS) and relapse-free survival (RFS) rates of HCC patients (P = 0.028 and P = 0.046, respectively). Surprisingly, high nuclear CD133 expression of HCC was an independent predictor of the good prognosis of the OS and RFS rates of HCC patients (P = 0.023 and P = 0.012, respectively).ConclusionsThe clinical evidence that revealed cytoplasmic CD133 expression was correlated with poor prognosis, while nuclear CD133 expression was significantly correlated with favorable prognosis.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3460-9) contains supplementary material, which is available to authorized users.

show abstract

Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas

Abstract: Our analysis represents the first complex study of these three putative CSCs markers together in three different types of pediatric sarcomas and showed their possible prognostic values in these tumors.

Cited by 17 publications

References 66 publications

Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes

Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes

Nestin expression in primary and metastatic uveal melanoma – possible biomarker for high‐risk uveal melanoma

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

Contact Info

Product

Resources

About